This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The state of California now allows certified nuclearmedicine technologists to administer any radiopharmaceuticals for therapeutic purposes. According to CDPH, the exemption remains valid until rescinded or until regulations modifying CTNM certification requirements and scope authorizations are adopted.
Total nuclearmedicine patient study volumes decreased by 5.7% Specifically considering cardiovascular nuclearmedicine procedures, total procedures have decreased by 7.1% million nuclearmedicine patient studies performed. Davin Korstjens of IMV Medical Information Division. Of these, 5.8 Nonhospitals 2.5%
Founded in 2019, the firm is focused on developing products for the diagnosis and therapy of blood cancers and other indications not addressed by nuclearmedicine.
With therapeutic radiopharmaceuticals coming to market quickly and available to smaller institutions around the U.S., My vision of a theranostic center includes a flagship facility that has a PET/CT scanner, a SPECT/CT scanner, and then multiple rooms for infusions of radiopharmaceuticals," Siegel explained.
As nuclearmedicine therapies gain stature compared to nuclearmedicine in diagnostic imaging, hospital administrators may be eyeing the potential of adding theranostics services. A shortage of nuclearmedicine technologists means a theranostics center may need to limit its patient volume.
In terms of 2023 spending, the average radiopharmaceutical expenditure per fixed PET site is estimated to be $517,000. In 2023, 38% of PET systems were operated by the PET department, 28% by nuclearmedicine, 24% by radiology/imaging, 5% by radiation oncology, and 2% by molecular imaging.
Theranostics treatments are used with increasing frequency now since the approvals and expansions of Lutathera (lutetium-177 [Lu-177]) DOTATATE, a radiopharmaceutical for neuroendrocrine tumors (NETs) and Pluvicto, Lu-177 PSMA-617, for prostate cancer.
The Society of NuclearMedicine and Molecular Imaging (SNMMI) has bestowed its Georg Charles de Hevesy Nuclear Pioneer award on Carolyn Anderson, PhD, of the University of Missouri-Columbia (MU). The award honors those who have made outstanding contributions in the field of nuclearmedicine, the SNMMI said.
Who made it to the final round in the 2024 edition of the Minnies, AuntMinnie.com 's event recognizing excellence in radiology? Most Influential Radiology Researcher Erik Middlebrooks, MD, Mayo Clinic, Jacksonville, FL Erik Middlebrooks, MD. Most Effective Radiology Educator Francis Deng, MD, Johns Hopkins Medicine Francis Deng, MD.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
With 100% of precincts now reporting, we’re finally ready to declare this year’s winners in our annual awards program recognizing excellence in radiology. The voters also zeroed in on the ongoing shortage of radiologists as the Biggest Threat to Radiology. Most Influential Radiology Researcher Minnies 2024 Winner: Erik H.
A decade ago, only a few radiopharmaceutical agents were used to help treat cancer patients. Hope, vice chair of clinical operations and strategy in the UCSF department of radiology, established the radioligand therapy group at the university. However, few freestanding theranostics centers exist today. Hope added.
Nuclearmedicine and the future of precise, personalised care in diagnosing and treating diseases. The post NuclearMedicine at the Centre of Radiology and Radiopharmaceuticals appeared first on Open Medscience.
Radiological societies have mixed views on the U.S. reduction in average Medicare payment rates compared with 2024, the CMS has estimated there will be a 0% change to reimbursement for radiology, nuclearmedicine, and radiation oncology. Although the 2025 MPFS calls for an overall 2.9%
A new AI PET/CT tool can assess patient cancer risk, predict tumor response, and estimate survival, according to research findings delivered June 10 at the Society of NuclearMedicine and Molecular Imaging (SNMMI) annual meeting in Toronto.
This leading radiopharmaceutical platform provides detailed PET imaging-based diagnosis and dosimetry using long-lived copper-64 ( 64 Cu) for imaging and alpha-particle targeted RPT using lead-212 ( 212 Pb). milla1cf Fri, 01/05/2024 - 11:21 January 5, 2024 — Perspective Therapeutics, Inc.
Anderson , PhD, a trailblazer in nuclearmedicine, has been named the 2024 recipient of the Georg Charles de Hevesy Nuclear Pioneer Award. The award was announced by the Society of NuclearMedicine and Molecular Imaging (SNMMI) during its 2024 Annual Meeting, June 8-11 in Toronto.
Food and Drug Administration's (FDA) approvals of radiopharmaceuticals for neuroendocrine tumors and then for prostate cancer, theranostics has picked up momentum in clinical practice, propelled by encouraging research. Since 2013 we've had several more radiopharmaceutical therapies get FDA approval.
Residency Training: Following medical school, radiologists enter a four-year residency in diagnostic radiology, where they learn to interpret medical images, perform imaging-guided procedures, and provide accurate diagnoses. Interventional Radiology (IR): This sub-specialty focuses on minimally invasive procedures guided by imaging.
Jean-Luc Urbain, MD, PhD, has been named president-elect of the Society of NuclearMedicine and Molecular Imaging (SNMMI). Urbain, a professor of radiology and nuclearmedicine, has served in multiple roles within SNMMI, in addition to his most recent post as vice president-elect. Jean-Luc Urbain, MD, PhD. “As
Evans, PhD, has been named the 2024 recipient of the Society of NuclearMedicine and Molecular Imaging (SNMMI) Sam Gambhir Trailblazer Award. He will be honored at the SNMMI's annual meeting in Toronto. Evans earned his PhD in organic chemistry from the Scripps Research Institute.
Dr. VanBrocklin is a professor in the Department of Radiology and Biomedical Imaging and director of the Radiopharmaceutical Research Program in the Center for Molecular and Functional Imaging at the University of California, San Francisco (UCSF). Congratulations to Henry VanBrocklin, PhD, FSNMMI, FSRS, recipient of the 2023 Paul C.
I congratulate Marco Campione on this CEO appointment and we look forward to drawing upon his strategic, operational and broad general business expertise as we increase our global leadership throughout the diagnostic radiopharmaceutical industry,” said Fulvio Renoldi Bracco, CEO of Bracco Imaging. Bracco Imaging S.p.A.,
Teleradiology-India Introduction: Nuclearmedicine continues to be at the forefront of cutting-edge technologies, pushing the boundaries of diagnostic and therapeutic capabilities. Revolutionary Radioisotopes: Expanding the Diagnostic Toolkit: Explore the latest developments in novel radioisotopes used in nuclearmedicine.
milla1cf Wed, 02/21/2024 - 18:58 February 21, 2024 — Blue Earth Therapeutics , a Bracco company and emerging leader in the development of innovative next generation therapeutic radiopharmaceuticals, is pleased to share the publication of promising early clinical data with 177Lu-rhPSMA-10.1 177Lu-rhPSMA-10.1
Mahmood was presented the award by the Society of NuclearMedicine and Molecular Imaging (SNMMI) at its 2023 Annual Meeting. Award recipients will have initiated, developed, and successfully implemented unique and significant transformative value within the field of nuclearmedicine and molecular imaging.
Teleradiology & Radiology data for artificial intelligence (AI) Introduction: Nuclearmedicine, a dynamic and rapidly evolving field, continues to break new ground in diagnostic and therapeutic approaches. Introduction to NuclearMedicine: Merging Physics and Medicine: Provide an overview of nuclearmedicine.
Blue Earth Therapeutics is highlighting early clinical results from a German trial investigating the use of a lutetium-177 (Lu-177)-labeled prostate specific antigen (PSMA) radiopharmaceutical. and its findings were published in December in the Journal of NuclearMedicine.
Data from theranostics is starting to focus on radiation dosimetry and dose limits in relation to kidney and other organ damage, said Nadine Mallak, MD, associate professor of body imaging and nuclearmedicine at Oregon Health and Science University in Portland.
She will also raise awareness of nuclearmedicine’s value to clinical colleagues and patients and will be laser-focused on breaking down barriers to radiopharmaceutical availability, reimbursement, affordability, and funding. An active SNMMI member, Jacene has been involved in many aspects of the organization.
Urbain, MD, PhD, FASNC, professor of Radiology/NuclearMedicine and Medicine, has been named president-elect of the Society of NuclearMedicine and Molecular Imaging (SNMMI). SNMMI introduced a new slate of officers during its 2024 Annual Meeting, held June 8-11 in Toronto. “As
By the end of June 2023, commercial production across the country will be underway at the 31 PETNET radiopharmacies Blue Earth Diagnostics included in its New Drug Application for POSLUMA, marking a record number of sites authorized for the manufacturing of a radiopharmaceutical upon its initial FDA approval.
For the practice of precision care in molecular imaging and nuclearmedicine, this begins with the production of radioisotopes for use in diagnostic tracers, which are administered to patients, attach to specific biomarkers, and release radioactive emissions to provide clinicians detailed molecular information unique to each patient.
As Theranostics and the use of radiopharmaceutical therapy (RPT) to treat cancer and other diseases have become more prevalent, interest in using dosimetry to personalize RPT treatments has grown. Dosimetry in Radiopharmaceutical Therapy. J Nucl Med. 2022 Oct;63(10):1467-1474. doi: 10.2967/jnumed.121.262305. 121.262305. [ii]
The “hybrid” scan – which combines molecular PET and anatomical CT images – may have its highest potential in visualizing early signs of so-called “perfusion deficits” (regions of obstructed blood flow), said Marcelo Di Carli, MD, a professor of radiology and medicine at Harvard Medical School, in a recent interview with AuntMinnie.com. “[PET/CT]
This year, hundreds of candidates have been selected as semifinalists for 14 categories, ranging from Most Influential Radiology Researcher to Best New Radiology Software. The semifinalist list was compiled based on nominations from members of AuntMinnie.com. Winners will be selected by our expert panel in two rounds of voting.
The announcement raises questions about the potential for supply interruptions for MRI contrast agents and radiopharmaceuticals based on these elements. In addition, radiopharmaceutical firm Curium Pharma is currently developing Lu-177 drug candidates for prostate cancer treatment and submitted a new drug application (NDA) with the U.S.
A nuclearmedicine hepatobiliary scan was also performed (not shown) and demonstrated no radiopharmaceutical present in the gallbladder due to cystic duct obstruction. 18.19669 Ian Rumball is a medical student and aspiring radiologist at the Zucker School of Medicine at Hofstra/Northwell in Hempstead, NY.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content